Vasopressin versus dopamine for treatment of hypotension in extremely low birth weight infants: a randomized, blinded
Danielle R Rios1, Jeffrey R Kaiser2
1Department of Pediatrics, Section of Neonatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX.
Insights
Vasopressin is a safe initial therapy for hypotension in extremely low birth weight (ELBW) infants, showing similar blood pressure response to dopamine. ELBW infants treated with vasopressin required less surfactant and had lower PaCO2 levels.
Area of Science:
- Neonatal Medicine
- Pediatric Pharmacology
- Critical Care
Background:
- Hypotension is a common complication in extremely low birth weight (ELBW) infants.
- Early intervention is crucial to prevent organ damage and improve outcomes in ELBW neonates.
Purpose of the Study:
- To compare the efficacy and safety of vasopressin versus dopamine as initial therapy for hypotension in ELBW infants within the first 24 hours of life.
Main Methods:
- A blinded, randomized trial involving ELBW infants (gestation ≤ 30 weeks) with early hypotension.
- Infants received either vasopressin or dopamine, with normotensive infants serving as a comparison group.
Main Results:
- Vasopressin and dopamine demonstrated similar efficacy in achieving adequate blood pressure in 90% of ELBW infants.
- The vasopressin group required fewer surfactant doses and had lower PaCO2 levels.
- Infants in the vasopressin group did not experience tachycardia, unlike the dopamine group.
Conclusions:
- Vasopressin is a safe and potentially beneficial initial treatment for early hypotension in ELBW infants.
- Results support further investigation through larger randomized controlled trials comparing vasopressin and dopamine.
Objective:
To evaluate vasopressin vs dopamine as initial therapy in extremely low birth weight (ELBW) infants with hypotension during the first 24 hours of life.
Study Design:
ELBW infants with hypertension ≤ 30 weeks' gestation and ≤ 24 hours old randomly received treatment with vasopressin or dopamine in a blinded fashion. Normotensive infants not receiving vasopressor support served as a comparison group.
Results:
Twenty ELBW infants with hypertension received vasopressin (n = 10) or dopamine (n = 10), and 50 were enrolled for comparison. Mean gestational age was 25.6 ± 1.4 weeks and birth weight 705 ± 154 g. Response to vasopressin paralleled that of dopamine in time to adequate mean blood pressure (Kaplan-Meier curve, P = .986); 90% of infants in each treatment group responded with adequate blood pressure. The vasopressin group received fewer doses of surfactant (P < .05), had lower PaCO2 values (P < .05), and were not tachycardic (P < .001) during vasopressin administration, compared with the dopamine group.
Conclusions:
Vasopressin in ELBW infants as the initial agent for early hypotension appeared safe. This pilot study supports a larger randomized controlled trial of vasopressin vs dopamine therapy in ELBW infants with hypotension.
Related Concept Videos
Antihypertensive Drugs: Vasodilators
Hormonal Regulation of Blood Pressure
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction...
Drug Dosing: Infants and Children
Adrenergic Antagonists: ɑ and β-Receptor Blockers
Hormonal Regulation
Diabetes Insipidus I: Introduction


